Controlling Pharmaceutical Risks analyses changes in drug testing since the late 1990s, specifically geneticization of carcinogenic risk assessment and regulation of pharmaceuticals, involving issues fundamental to bio-science, medical treatment and patients¿ health, such as what knowledge is judged necessary to determine carcinogenic risk to humans, and how that judgement transpired.
Prenumerera på vårt nyhetsbrev för att få fantastiska erbjudanden och inspiration för din nästa läsning.
Genom att registrera dig accepterar du vår personuppgiftspolicy.